Your browser doesn't support javascript.
Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults.
Ma, Yue; Zhang, Yuan; Li, Shu; Yang, Hongxi; Li, Huiping; Cao, Zhi; Xu, Fusheng; Sun, Li; Wang, Yaogang.
  • Ma Y; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Zhang Y; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Li S; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Yang H; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Li H; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Cao Z; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Xu F; Department of Epidemiology and Health Statistics, School of Public Health, Zhejiang University, Hangzhou, China.
  • Sun L; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
  • Wang Y; School of Public Health, Tianjin Medical University, Tianjin, 300070, China.
Drugs Aging ; 38(10): 921-930, 2021 10.
Article in English | MEDLINE | ID: covidwho-1361350
ABSTRACT

BACKGROUND:

There is ongoing debate about the associations between drug therapies targeting the renin-angiotensin-aldosterone system (RAAS) and adverse outcomes in coronavirus disease 2019 (COVID-19).

OBJECTIVE:

This study aims to examine the associations between using medications for the cardiovascular system and the risks associated with COVID-19 in middle-aged and older adults.

METHODS:

A total of 77,221 participants (aged 50-86 years) from UK Biobank were tested for SARS-CoV-2 RNA. The medications included angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), ß-blockers, calcium channel blockers (CCB), statins, and aspirin. COVID-19 outcomes comprised a positive test result and severity of COVID-19 (defined as mild, hospitalization or death). We evaluated the risk among total participants and for sub-groups based on sex. Propensity score matching was performed 11 and logistic regression models were used.

RESULTS:

Among the middle- and older aged participants, no significant associations between any class of medications and the likelihood of COVID-19 infection were observed. ACEI were associated with a higher mortality risk from COVID-19 (odds ratio [OR] 1.15, 95% confidence interval [CI] 1.01-1.32) and CCB were associated with a lower hospitalization risk for COVID-19 (OR 0.87, 95% CI 0.79-0.96) among the male patients with COVID-19, while a lower mortality risk from COVID-19 (OR 0.67, 95% CI 0.47-0.96) was observed with ARB among the female patients with COVID-19.

CONCLUSIONS:

The study suggested sex differences in the risk of death from COVID-19 with the use of ACEI and ARB among middle-aged and older adults. Sex differences in the risk of hospitalization for COVID-19 with the use of CCB was observed as well. It is of clinical importance that clinicians adopt different CVD treatment approaches for female and male patients with COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Drugs Aging Journal subject: Geriatrics / Drug Therapy Year: 2021 Document Type: Article Affiliation country: S40266-021-00886-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Drugs Aging Journal subject: Geriatrics / Drug Therapy Year: 2021 Document Type: Article Affiliation country: S40266-021-00886-y